IMMU-27. Re-MATCH PROTOCOL: PHASE I STUDY OF AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (ALT) + DC VACCINE (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND AUTOLOGOUS STEM CELL RESCUE (HDC + ASCR) OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) IN PATIENTS WITH RECURRENT CENTRAL PNETs (r-PNET)

We performed a phase I study to assess feasibility, safety, and efficacy of ALT+DCV following HDC +ASCR (group A) or NMAC (group B) in pts with r-PNET. METHODS: Eligible pts underwent surgery to confirm diagnosis and obtain tumor for vaccine preparation. Pts with local (group A) or metastatic (group...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Gururangan, Sridharan, Grant, Gerald, Driscoll, Tim, Archer, Gerald, Herndon, James, Friedman, Henry, Kurtzberg, Joanne, Bigner, Darell, Sampson, John, Mitchell, Duane
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012948/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.343
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars